Pinned post
In order to foster a safe and respectful space for our community, we ask that users adhere to these guidelines when commenting.
Thread below🧵⬇️
Thread below🧵⬇️
MedPage Today
@medpagetoday
5.8K Following 73K Followers 64K Posts
Latest posts 5
ICYMI: “What are the next steps in terms of bringing this closer to being a clinical application?” #arthritis @ACRheum #Rheumatology
Read more: bit.ly/4AgEdZn
www.medpagetoday.com In Pursuit of New Predictive Tools for RA-Interstitial Lung Disease A group of peripheral biomarker signatures improved interstitial lung disease (ILD) discrimination beyond clinical risk factors alone in a large cohort of people with rheumatoid arthritis (RA).... Read more: bit.ly/4AgEdZn
The FDA on Friday approved injectable gefurulimab (Klygefa), a dual-binding nanobody that blocks complement component 5 activation, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
medpagetoday.com/neurology/gene…
medpagetoday.com/neurology/gene…
www.medpagetoday.com Injectable Nanobody Wins FDA Approval for Myasthenia Gravis Gefurulimab joins other approved C5 inhibitors People with early-onset Alzheimer's disease had faster and more severe accumulation of tau than those whose Alzheimer's symptoms started after age 65, imaging data showed. medpagetoday.com/neurology/alzh…
www.medpagetoday.com Alzheimer's Study Tracks Faster Tau Buildup in Younger Patients Tau spread more rapidly across a wider area of the brain in early-onset Alzheimer's disease Shifting gears on prostate cancer screening, the American Cancer Society now recommends screening with prostate-specific antigen every 2 years for average-risk men ages 50 to 69. medpagetoday.com/hematologyonco…
www.medpagetoday.com Major Change to Prostate Cancer Screening Guidelines ACS now recommends PSA testing every 2 years for average-risk men ages 50 to 69